New drugs may help limit the damage that HIV does to your immune system. What can a HIV+ person do to minimize the risk of opportunistic infections? Can the side effects of protease inhibitors be avoided or the damage they cause mitigated?
Opportunistic infections in HIV+ patients generally result after the disease has progressed to AIDS (generally defined as a T-cell count lower than 200 parts per millileter). Some infections can occur in individuals who do not yet have AIDS, and new drug therapies are decreasing the incidence of many infections. Nevertheless, avoiding opportunistic infections when possible and treating them promptly when they occur can have a significant positive impact on overall health.
An overview document by the National Institutes of Health. Learn to identify some of the common opportunistic infections in HIV+ people by recognizing early symptoms and getting prompt medical treatment.
Tuberculosis is a serious disease that has experienced a recent resurgence in HIV+ people. This overview brochure talks about some of the symptoms of TB and how it is successfully treated.
Centers for Disease Control and Prevention brochures on prevention of common opportunistic infections, including Cryptosporidium, Cytomegalovirus (CMV), and Toxoplasmosis.
Current therapies that are successfully lowering viral load in patients and restoring their immune function often have difficult side effects. Unfortunately, government sites do not yet contain information about these effects of therapy. The sites below are good starting points for information about what you might expect while taking protease inhibitors. For further information, check the links on the News and Updates page often.
|
|